Oncologie

, Volume 18, Issue 1, pp 76–80 | Cite as

Brèves de l’AERIO

Androgen receptor splice variant 7 et efficacité des taxanes dans le cancer de la prostate résistant à la castration
Revue de Presse de L’Aerio / Aerio Press Review

AERIO News in Brief

Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Nadiminty N, Tummala R, Liu C, et al. (2013) NF-êB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther 12: 1629–37PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Antonarakis ES, Lu C, Wang H, et al. (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371: 1028–38PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Antonarakis ES, Lu C, Luber B, et al. (2015) Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol 1: 582–91PubMedCrossRefGoogle Scholar
  4. 1.
    Finn RS, Dering J, Conklin D, et al. (2009) PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 11: R77PubMedPubMedCentralCrossRefGoogle Scholar
  5. 2.
    DeMichele A, Clark AS, Tan KS, et al. (2015) CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin Cancer Res 21: 995–1001PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag France 2016

Authors and Affiliations

  1. 1.AERIOParisFrance
  2. 2.Hôpital européen Georges-Pompidou (HEGP)ParisFrance
  3. 3.AERIOParisFrance
  4. 4.Gustave-RoussyVillejuif cedexFrance

Personalised recommendations